Published in Prostate on June 15, 2004
The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta (2007) 2.82
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer (2010) 1.26
Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem (2009) 1.12
Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J Transl Med (2006) 1.02
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol (2008) 1.00
The effects of depression and use of antidepressive medicines during pregnancy on the methylation status of the IGF2 imprinted control regions in the offspring. Clin Epigenetics (2011) 1.00
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
Heterogeneity of DNA methylation in multifocal prostate cancer. Virchows Arch (2014) 0.95
DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol (2012) 0.88
Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors. Prostate (2009) 0.85
Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. PLoS One (2014) 0.84
The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. PLoS One (2013) 0.81
Prostate cancer epigenetics: a review on gene regulation. Gene Regul Syst Bio (2007) 0.81
Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis. PLoS One (2013) 0.80
COX-2 (PTGS2) gene methylation in epithelial, subepithelial lymphocyte and stromal tissue compartments in a spectrum of esophageal squamous neoplasia. Cancer Detect Prev (2008) 0.77
Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells. Pharmacol Res (2016) 0.75
Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol (2017) 0.75
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
von Hippel-Lindau disease. Lancet (2003) 6.20
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med (2004) 2.72
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol (2009) 2.27
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Carbon nanotube amplification strategies for highly sensitive immunodetection of cancer biomarkers. J Am Chem Soc (2006) 2.19
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell (2011) 2.12
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet (2010) 2.06
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab (2006) 2.04
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol (2013) 1.96
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol (2007) 1.86
Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene (2008) 1.82
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78
Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem (2004) 1.76
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes. J Urol (2010) 1.74
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies. Int J Cancer (2013) 1.71
Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol (2010) 1.67
Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod Pathol (2004) 1.67
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer (2002) 1.65
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther (2004) 1.58
Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2006) 1.58
Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A (2003) 1.53
Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest (2010) 1.52
Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation (2010) 1.52
Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla. BJU Int (2012) 1.51
Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics (2003) 1.50
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer (2011) 1.49
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. Eur Urol (2008) 1.48
Renal cell carcinoma with metastases to the gallbladder: four cases from the National Cancer Institute (NCI) and review of the literature. Urol Oncol (2011) 1.48
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res (2002) 1.47
Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina (2007) 1.46
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45
Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 1.44
Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol (2007) 1.43
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet (2011) 1.43
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell (2006) 1.41
Feasibility and outcomes of repeat partial nephrectomy. J Urol (2008) 1.41
Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res (2004) 1.40
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood (2004) 1.39
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist (2012) 1.33
Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis. J Urol (2008) 1.33
Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res (2003) 1.31
Hereditary renal cancers. Radiology (2003) 1.31
Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling. Mol Cancer (2010) 1.30
Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. Urology (2012) 1.28
Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging (2013) 1.27
Neurologic manifestations of von Hippel-Lindau disease. JAMA (2008) 1.26
The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res (2002) 1.26
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res (2006) 1.26
The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dubé gene pathway. Cancer Genet Cytogenet (2008) 1.24
Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control (2003) 1.23
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One (2010) 1.23
Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based case-control study. J Urol (2010) 1.23
Partial nephrectomy after previous radio frequency ablation: the National Cancer Institute experience. J Urol (2009) 1.21
Targeting cancer metabolism. Clin Cancer Res (2012) 1.21
Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer (2010) 1.21
Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol (2004) 1.20